Biomarkers /
PR
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
PR is a predictive biomarker for use of fulvestrant, aromatase inhibitor, everolimus, exemestane, trastuzumab, anastrozole, letrozole, abemaciclib, endocrine therapy, tamoxifen, alpelisib, lapatinib, palbociclib, ribociclib, ado-trastuzumab emtansine, atezolizumab, ivosidenib, nab-paclitaxel, pembrolizumab, pertuzumab, sacituzumab govitecan, and toremifene in patients.
Breast carcinoma and breast invasive lobular carcinoma have the most therapies with PR as a predictive biomarker.
Of the therapies with PR as a predictive biomarker, 17 are FDA-approved in at least one clinical setting and 21 have NCCN guidelines in at least one clinical setting.
PR Expression, PR Positive, PR Negative, and PR No Expression are the top alterations on PR targeted by therapies [4].
Abemaciclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. |
Anastrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for locally advanced or metastatic breast cancer as first-line treatment or after progression on tamoxifen. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NICE, SMC) | |
| Note: Please note that NICE guidance stipulates estrogen receptor (ER) expression as the criterion for primary adjuvant therapy with anastrozole, not progesterone receptor (PR). |
Everolimus +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for metastatic disease. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, and for HR-positive advanced disease with progression following endocrine therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Ivosidenib +
Breast Invasive Lobular Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Sensitive |
| Clinical Setting(s): Metastatic (BNF) |
Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for advanced breast cancer as first-line treatment or after progression following antiestrogen therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Neoadjuvant (BNF) |
Pembrolizumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) >= 10]. |
Sacituzumab Govitecan +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. |
Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR+ breast cancer, both as adjuvant treatment and in the metastatic setting. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE) |
Toremifene +
Breast Carcinoma -
Abemaciclib + Aromatase Inhibitor +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. |
Abemaciclib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Ado-Trastuzumab Emtansine + Endocrine Therapy +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer. |
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: PIK3CA E545Q, PIK3CA Q546K, PIK3CA Q546P, PIK3CA E365K, PIK3CA E453K, PIK3CA G1049R, PIK3CA G106V, PIK3CA G118D, PIK3CA K111E, PIK3CA K111N, PIK3CA M1043I, PIK3CA M1043V, PIK3CA N345K, PIK3CA P447_L455del, PIK3CA P539R, PIK3CA R108H, PIK3CA R88Q, PIK3CA R93W, PIK3CA T1025A, PIK3CA V344G, PIK3CA V344M Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative, PIK3CA-mutated, recurrent or metastatic breast cancer. |
Anastrozole + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as first line therapy. |
Aromatase Inhibitor + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved with letrozole as the aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. NCCN recommended for any aromatase inhibitor. |
Aromatase Inhibitor + Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positve/HER2-positive recurrent or metastastic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in postmenopausal women or in men. |
Aromatase Inhibitor + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. |
Aromatase Inhibitor + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Atezolizumab + Nab-Paclitaxel +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area. |
Endocrine Therapy + Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer, with or without chemotherapy. |
Endocrine Therapy + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) | |
| Note: Recommend for HR-positive/HER2-positive breast cancer, with fulvestrant, tamoxifen, or aromatase inhibitor metastastic disease, or with tamoxifen or aromatase inhibitor for adjuvant treatment. |
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with advanced HR+, HER2- breast cancer after failure of treatment with letrozole or anastrozole. |
Everolimus + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as subsequent line therapy. |
Everolimus + Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as subsequent line therapy. |
Fulvestrant + Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as first line therapy. |
Fulvestrant + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Fulvestrant + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy, or following disease progression on endocrine therapy. |
Clinical Trials
PR status serves as an inclusion eligibility criteria in 810 clinical trials, of which 576 are open and 234 are closed. Of the trials that contain PR status as an inclusion criterion, 19 are early phase 1 (14 open), 215 are phase 1 (134 open), 138 are phase 1/phase 2 (101 open), 307 are phase 2 (222 open), 8 are phase 2/phase 3 (7 open), 85 are phase 3 (69 open), 6 are phase 4 (2 open), and 32 are no phase specified (27 open).
Trials with PR status in the inclusion eligibility criteria most commonly target breast carcinoma, invasive breast carcinoma, breast adenocarcinoma, breast invasive ductal carcinoma, and ductal carcinoma in situ [4].
The most frequent alterations to serve as inclusion eligibility criteria are PR Negative, PR No Expression, PR Positive, and PR Expression [4].
Pembrolizumab, paclitaxel, fulvestrant, carboplatin, and cyclophosphamide are the most frequent therapies in trials with PR as an inclusion criteria [4].
Significance of PR in Diseases
Breast Carcinoma +
PR is an inclusion criterion in 707 clinical trials for breast carcinoma, of which 482 are open and 225 are closed. Of the trials that contain PR status and breast carcinoma as inclusion criteria, 14 are early phase 1 (9 open), 201 are phase 1 (123 open), 130 are phase 1/phase 2 (95 open), 257 are phase 2 (174 open), 7 are phase 2/phase 3 (6 open), 68 are phase 3 (53 open), 6 are phase 4 (2 open), and 24 are no phase specified (20 open) [4].
Anastrozole, letrozole, fulvestrant, exemestane, everolimus, tamoxifen, alpelisib, aromatase inhibitor, trastuzumab, abemaciclib, sacituzumab govitecan, pembrolizumab, ribociclib, palbociclib, endocrine therapy, pertuzumab, atezolizumab, nab-paclitaxel, lapatinib, ado-trastuzumab emtansine, and toremifene have evidence of efficacy in patients with PR mutation in breast carcinoma [4].
Breast Invasive Lobular Carcinoma +
PR is an inclusion criterion in 4 clinical trials for breast invasive lobular carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PR status and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Ivosidenib has evidence of efficacy in patients with PR mutation in breast invasive lobular carcinoma [4].
Malignant Solid Tumor +
PR is an inclusion criterion in 126 clinical trials for malignant solid tumor, of which 86 are open and 40 are closed. Of the trials that contain PR status and malignant solid tumor as inclusion criteria, 82 are phase 1 (50 open), 34 are phase 1/phase 2 (27 open), and 10 are phase 2 (9 open) [4].
Non-Small Cell Lung Carcinoma +
PR is an inclusion criterion in 101 clinical trials for non-small cell lung carcinoma, of which 66 are open and 35 are closed. Of the trials that contain PR status and non-small cell lung carcinoma as inclusion criteria, 57 are phase 1 (33 open), 29 are phase 1/phase 2 (21 open), 14 are phase 2 (11 open), and 1 is phase 3 (1 open) [4].
Ovarian Carcinoma +
PR is an inclusion criterion in 87 clinical trials for ovarian carcinoma, of which 55 are open and 32 are closed. Of the trials that contain PR status and ovarian carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 52 are phase 1 (26 open), 24 are phase 1/phase 2 (20 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].
Colorectal Carcinoma +
PR is an inclusion criterion in 60 clinical trials for colorectal carcinoma, of which 39 are open and 21 are closed. Of the trials that contain PR status and colorectal carcinoma as inclusion criteria, 38 are phase 1 (23 open), 17 are phase 1/phase 2 (13 open), 4 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].
Head And Neck Squamous Cell Carcinoma +
PR is an inclusion criterion in 53 clinical trials for head and neck squamous cell carcinoma, of which 38 are open and 15 are closed. Of the trials that contain PR status and head and neck squamous cell carcinoma as inclusion criteria, 32 are phase 1 (21 open), 16 are phase 1/phase 2 (13 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Invasive Breast Carcinoma +
PR is an inclusion criterion in 49 clinical trials for invasive breast carcinoma, of which 46 are open and 3 are closed. Of the trials that contain PR status and invasive breast carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 29 are phase 2 (28 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (8 open), and 1 is no phase specified (1 open) [4].
Melanoma +
PR is an inclusion criterion in 48 clinical trials for melanoma, of which 31 are open and 17 are closed. Of the trials that contain PR status and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 26 are phase 1 (16 open), 10 are phase 1/phase 2 (8 open), 10 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].
Gastric Carcinoma +
PR is an inclusion criterion in 42 clinical trials for gastric carcinoma, of which 26 are open and 16 are closed. Of the trials that contain PR status and gastric carcinoma as inclusion criteria, 23 are phase 1 (12 open), 12 are phase 1/phase 2 (9 open), 6 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].
Urothelial Carcinoma +
PR is an inclusion criterion in 39 clinical trials for urothelial carcinoma, of which 28 are open and 11 are closed. Of the trials that contain PR status and urothelial carcinoma as inclusion criteria, 20 are phase 1 (12 open), 13 are phase 1/phase 2 (10 open), and 6 are phase 2 (6 open) [4].
Renal Cell Carcinoma +
PR is an inclusion criterion in 37 clinical trials for renal cell carcinoma, of which 23 are open and 14 are closed. Of the trials that contain PR status and renal cell carcinoma as inclusion criteria, 20 are phase 1 (9 open), 10 are phase 1/phase 2 (8 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].
Fallopian Tube Carcinoma +
PR is an inclusion criterion in 35 clinical trials for fallopian tube carcinoma, of which 22 are open and 13 are closed. Of the trials that contain PR status and fallopian tube carcinoma as inclusion criteria, 25 are phase 1 (14 open), 7 are phase 1/phase 2 (6 open), and 3 are phase 2 (2 open) [4].
Small Cell Lung Carcinoma +
PR is an inclusion criterion in 34 clinical trials for small cell lung carcinoma, of which 25 are open and 9 are closed. Of the trials that contain PR status and small cell lung carcinoma as inclusion criteria, 16 are phase 1 (10 open), 14 are phase 1/phase 2 (11 open), and 4 are phase 2 (4 open) [4].
Endometrial Carcinoma +
PR is an inclusion criterion in 33 clinical trials for endometrial carcinoma, of which 27 are open and 6 are closed. Of the trials that contain PR status and endometrial carcinoma as inclusion criteria, 18 are phase 1 (15 open), 13 are phase 1/phase 2 (10 open), and 2 are phase 2 (2 open) [4].
Primary Peritoneal Carcinoma +
PR is an inclusion criterion in 32 clinical trials for primary peritoneal carcinoma, of which 19 are open and 13 are closed. Of the trials that contain PR status and primary peritoneal carcinoma as inclusion criteria, 23 are phase 1 (12 open), 6 are phase 1/phase 2 (5 open), and 3 are phase 2 (2 open) [4].
Prostate Carcinoma +
PR is an inclusion criterion in 30 clinical trials for prostate carcinoma, of which 19 are open and 11 are closed. Of the trials that contain PR status and prostate carcinoma as inclusion criteria, 17 are phase 1 (8 open), 10 are phase 1/phase 2 (9 open), and 3 are phase 2 (2 open) [4].
Breast Adenocarcinoma +
PR is an inclusion criterion in 29 clinical trials for breast adenocarcinoma, of which 27 are open and 2 are closed. Of the trials that contain PR status and breast adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (6 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (7 open), 9 are phase 3 (8 open), and 3 are no phase specified (3 open) [4].
Pancreatic Carcinoma +
PR is an inclusion criterion in 29 clinical trials for pancreatic carcinoma, of which 22 are open and 7 are closed. Of the trials that contain PR status and pancreatic carcinoma as inclusion criteria, 16 are phase 1 (11 open), 11 are phase 1/phase 2 (9 open), and 2 are phase 2 (2 open) [4].
Cervical Carcinoma +
PR is an inclusion criterion in 28 clinical trials for cervical carcinoma, of which 23 are open and 5 are closed. Of the trials that contain PR status and cervical carcinoma as inclusion criteria, 18 are phase 1 (14 open), 7 are phase 1/phase 2 (6 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
PR is an inclusion criterion in 24 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 18 are open and 6 are closed. Of the trials that contain PR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 14 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].
Bladder Carcinoma +
PR is an inclusion criterion in 24 clinical trials for bladder carcinoma, of which 14 are open and 10 are closed. Of the trials that contain PR status and bladder carcinoma as inclusion criteria, 15 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].
Hepatocellular Carcinoma +
PR is an inclusion criterion in 24 clinical trials for hepatocellular carcinoma, of which 20 are open and 4 are closed. Of the trials that contain PR status and hepatocellular carcinoma as inclusion criteria, 13 are phase 1 (10 open), 9 are phase 1/phase 2 (8 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Esophageal Carcinoma +
PR is an inclusion criterion in 20 clinical trials for esophageal carcinoma, of which 14 are open and 6 are closed. Of the trials that contain PR status and esophageal carcinoma as inclusion criteria, 7 are phase 1 (3 open), 10 are phase 1/phase 2 (9 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Pancreatic Adenocarcinoma +
PR is an inclusion criterion in 15 clinical trials for pancreatic adenocarcinoma, of which 9 are open and 6 are closed. Of the trials that contain PR status and pancreatic adenocarcinoma as inclusion criteria, 9 are phase 1 (6 open), 5 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Gastric Adenocarcinoma +
PR is an inclusion criterion in 12 clinical trials for gastric adenocarcinoma, of which 10 are open and 2 are closed. Of the trials that contain PR status and gastric adenocarcinoma as inclusion criteria, 7 are phase 1 (5 open) and 5 are phase 1/phase 2 (5 open) [4].
Head And Neck Carcinoma +
PR is an inclusion criterion in 12 clinical trials for head and neck carcinoma, of which 8 are open and 4 are closed. Of the trials that contain PR status and head and neck carcinoma as inclusion criteria, 9 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Soft Tissue Sarcoma +
PR is an inclusion criterion in 12 clinical trials for soft tissue sarcoma, of which 6 are open and 6 are closed. Of the trials that contain PR status and soft tissue sarcoma as inclusion criteria, 8 are phase 1 (2 open) and 4 are phase 1/phase 2 (4 open) [4].
Lymphoma +
PR is an inclusion criterion in 11 clinical trials for lymphoma, of which 6 are open and 5 are closed. Of the trials that contain PR status and lymphoma as inclusion criteria, 8 are phase 1 (4 open) and 3 are phase 1/phase 2 (2 open) [4].
Squamous Cell Lung Carcinoma +
PR is an inclusion criterion in 11 clinical trials for squamous cell lung carcinoma, of which 8 are open and 3 are closed. Of the trials that contain PR status and squamous cell lung carcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Glioblastoma +
PR is an inclusion criterion in 10 clinical trials for glioblastoma, of which 6 are open and 4 are closed. Of the trials that contain PR status and glioblastoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Mesothelioma +
PR is an inclusion criterion in 9 clinical trials for mesothelioma, of which 6 are open and 3 are closed. Of the trials that contain PR status and mesothelioma as inclusion criteria, 9 are phase 1 (6 open) [4].
Pancreatic Ductal Adenocarcinoma +
PR is an inclusion criterion in 9 clinical trials for pancreatic ductal adenocarcinoma, of which 5 are open and 4 are closed. Of the trials that contain PR status and pancreatic ductal adenocarcinoma as inclusion criteria, 6 are phase 1 (5 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (0 open) [4].
Merkel Cell Carcinoma +
PR is an inclusion criterion in 8 clinical trials for Merkel cell carcinoma, of which 7 are open and 1 is closed. Of the trials that contain PR status and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 4 are phase 1/phase 2 (4 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Sarcoma +
PR is an inclusion criterion in 8 clinical trials for sarcoma, of which 5 are open and 3 are closed. Of the trials that contain PR status and sarcoma as inclusion criteria, 4 are phase 1 (2 open) and 4 are phase 1/phase 2 (3 open) [4].
Ductal Carcinoma In Situ +
PR is an inclusion criterion in 7 clinical trials for ductal carcinoma in situ, of which 6 are open and 1 is closed. Of the trials that contain PR status and ductal carcinoma in situ as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 2 (2 open), and 3 are no phase specified (3 open) [4].
Prostate Adenocarcinoma +
PR is an inclusion criterion in 7 clinical trials for prostate adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain PR status and prostate adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open) and 2 are phase 1/phase 2 (1 open) [4].
Breast Invasive Ductal Carcinoma +
PR is an inclusion criterion in 6 clinical trials for breast invasive ductal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PR status and breast invasive ductal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 2 are no phase specified (1 open) [4].
Cholangiocarcinoma +
PR is an inclusion criterion in 6 clinical trials for cholangiocarcinoma, of which 4 are open and 2 are closed. Of the trials that contain PR status and cholangiocarcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Clear Cell Renal Cell Carcinoma +
PR is an inclusion criterion in 6 clinical trials for clear cell renal cell carcinoma, of which 4 are open and 2 are closed. Of the trials that contain PR status and clear cell renal cell carcinoma as inclusion criteria, 5 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].
Nasopharyngeal Carcinoma +
PR is an inclusion criterion in 6 clinical trials for nasopharyngeal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PR status and nasopharyngeal carcinoma as inclusion criteria, 5 are phase 1 (4 open) and 1 is phase 1/phase 2 (1 open) [4].
Non-Hodgkin Lymphoma +
PR is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain PR status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (6 open) [4].
Acute Myeloid Leukemia +
PR is an inclusion criterion in 5 clinical trials for acute myeloid leukemia, of which 4 are open and 1 is closed. Of the trials that contain PR status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [4].
Cancer +
PR is an inclusion criterion in 5 clinical trials for cancer, of which 2 are open and 3 are closed. Of the trials that contain PR status and cancer as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].
Colorectal Adenocarcinoma +
PR is an inclusion criterion in 5 clinical trials for colorectal adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain PR status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [4].
Endometrial Endometrioid Adenocarcinoma +
PR is an inclusion criterion in 5 clinical trials for endometrial endometrioid adenocarcinoma, of which 3 are open and 2 are closed. Of the trials that contain PR status and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (0 open) and 3 are phase 2 (3 open) [4].
Esophageal Squamous Cell Carcinoma +
PR is an inclusion criterion in 5 clinical trials for esophageal squamous cell carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PR status and esophageal squamous cell carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
PR is an inclusion criterion in 5 clinical trials for high grade ovarian serous adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain PR status and high grade ovarian serous adenocarcinoma as inclusion criteria, 5 are phase 1 (4 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
PR is an inclusion criterion in 5 clinical trials for non-squamous non-small cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PR status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Peritoneal Mesothelioma +
PR is an inclusion criterion in 5 clinical trials for peritoneal mesothelioma, of which 2 are open and 3 are closed. Of the trials that contain PR status and peritoneal mesothelioma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Skin Squamous Cell Carcinoma +
PR is an inclusion criterion in 5 clinical trials for skin squamous cell carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PR status and skin squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [4].
Biliary Tract Carcinoma +
PR is an inclusion criterion in 4 clinical trials for biliary tract carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PR status and biliary tract carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Carcinoma +
PR is an inclusion criterion in 4 clinical trials for carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PR status and carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [4].
Chronic Lymphocytic Leukemia +
PR is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain PR status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].
Diffuse Large B-Cell Lymphoma +
PR is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain PR status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Esophagogastric Carcinoma +
PR is an inclusion criterion in 4 clinical trials for esophagogastric carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PR status and esophagogastric carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [4].
Inflammatory Breast Carcinoma +
PR is an inclusion criterion in 4 clinical trials for inflammatory breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PR status and inflammatory breast carcinoma as inclusion criteria, 4 are phase 2 (4 open) [4].
Lung Adenocarcinoma +
PR is an inclusion criterion in 4 clinical trials for lung adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain PR status and lung adenocarcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Malignant Uterine Neoplasm +
PR is an inclusion criterion in 4 clinical trials for malignant uterine neoplasm, of which 4 are open and 0 are closed. Of the trials that contain PR status and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Multiple Myeloma +
PR is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 3 are open and 1 is closed. Of the trials that contain PR status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [4].
Adenoid Cystic Carcinoma +
PR is an inclusion criterion in 3 clinical trials for adenoid cystic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR status and adenoid cystic carcinoma as inclusion criteria, 3 are phase 1 (2 open) [4].
Colon Carcinoma +
PR is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR status and colon carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Cutaneous Melanoma +
PR is an inclusion criterion in 3 clinical trials for cutaneous melanoma, of which 3 are open and 0 are closed. Of the trials that contain PR status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Endometrial Mixed Adenocarcinoma +
PR is an inclusion criterion in 3 clinical trials for endometrial mixed adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR status and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].
Endometrial Serous Adenocarcinoma +
PR is an inclusion criterion in 3 clinical trials for endometrial serous adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PR status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Esophageal Adenocarcinoma +
PR is an inclusion criterion in 3 clinical trials for esophageal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PR status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].
Malignant Ovarian Epithelial Tumor +
PR is an inclusion criterion in 3 clinical trials for malignant ovarian epithelial tumor, of which 3 are open and 0 are closed. Of the trials that contain PR status and malignant ovarian epithelial tumor as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Mantle Cell Lymphoma +
PR is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain PR status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].
Ovarian Endometrioid Adenocarcinoma +
PR is an inclusion criterion in 3 clinical trials for ovarian endometrioid adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR status and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Pleural Mesothelioma +
PR is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 0 are open and 3 are closed. Of the trials that contain PR status and pleural mesothelioma as inclusion criteria, 3 are phase 1 (0 open) [4].
Thymic Carcinoma +
PR is an inclusion criterion in 3 clinical trials for thymic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PR status and thymic carcinoma as inclusion criteria, 3 are phase 1 (3 open) [4].
Acute Lymphoblastic Leukemia +
PR is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain PR status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Anal Canal Squamous Cell Carcinoma +
PR is an inclusion criterion in 2 clinical trials for anal canal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Anal Carcinoma +
PR is an inclusion criterion in 2 clinical trials for anal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and anal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].
Anaplastic Astrocytoma +
PR is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain PR status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
PR is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].
Breast Lobular Carcinoma In Situ +
PR is an inclusion criterion in 2 clinical trials for breast lobular carcinoma in situ, of which 2 are open and 0 are closed. Of the trials that contain PR status and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [4].
Cervical Squamous Cell Carcinoma +
PR is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and cervical squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Classical Hodgkin Lymphoma +
PR is an inclusion criterion in 2 clinical trials for classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Endometrial Adenocarcinoma +
PR is an inclusion criterion in 2 clinical trials for endometrial adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PR status and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Endometrial Clear Cell Adenocarcinoma +
PR is an inclusion criterion in 2 clinical trials for endometrial clear cell adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and endometrial clear cell adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Endometrial Undifferentiated Carcinoma +
PR is an inclusion criterion in 2 clinical trials for endometrial undifferentiated carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and endometrial undifferentiated carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Gallbladder Carcinoma +
PR is an inclusion criterion in 2 clinical trials for gallbladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and gallbladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Gastrointestinal Stromal Tumor +
PR is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain PR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Hematopoietic And Lymphoid Malignancy +
PR is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain PR status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
High Grade Fallopian Tube Serous Adenocarcinoma +
PR is an inclusion criterion in 2 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PR status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Intrahepatic Cholangiocarcinoma +
PR is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Malignant Pleural Mesothelioma +
PR is an inclusion criterion in 2 clinical trials for malignant pleural mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain PR status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Medullary Breast Carcinoma +
PR is an inclusion criterion in 2 clinical trials for medullary breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and medullary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Mixed Lobular And Ductal Breast Carcinoma +
PR is an inclusion criterion in 2 clinical trials for mixed lobular and ductal breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Myelodysplastic Syndromes +
PR is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain PR status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].
Neuroendocrine Carcinoma +
PR is an inclusion criterion in 2 clinical trials for neuroendocrine carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PR status and neuroendocrine carcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
PR is an inclusion criterion in 2 clinical trials for oropharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Ovarian Epithelial Tumor +
PR is an inclusion criterion in 2 clinical trials for ovarian epithelial tumor, of which 1 is open and 1 is closed. Of the trials that contain PR status and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].
Primary Peritoneal Serous Adenocarcinoma +
PR is an inclusion criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Thymoma +
PR is an inclusion criterion in 2 clinical trials for thymoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and thymoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Thyroid Gland Carcinoma +
PR is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Vulvar Carcinoma +
PR is an inclusion criterion in 2 clinical trials for vulvar carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR status and vulvar carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Adnexal Carcinoma +
PR is an inclusion criterion in 1 clinical trial for adnexal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and adnexal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Anal Squamous Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
PR is an inclusion criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
B-Cell Neoplasm +
PR is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PR status and B-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Basal Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Benign Breast Neoplasm +
PR is an inclusion criterion in 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PR status and benign breast neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Bilateral Breast Carcinoma +
PR is an inclusion criterion in 1 clinical trial for bilateral breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and bilateral breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bladder Urothelial Carcinoma +
PR is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cervical Carcinosarcoma +
PR is an inclusion criterion in 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and cervical carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Chordoma +
PR is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and chordoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Desmoid-Type Fibromatosis +
PR is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PR status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1 (1 open) [4].
Double-Hit Lymphoma +
PR is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and double-hit lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Endometrial Dedifferentiated Carcinoma +
PR is an inclusion criterion in 1 clinical trial for endometrial dedifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and endometrial dedifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Endometrial Mucinous Adenocarcinoma +
PR is an inclusion criterion in 1 clinical trial for endometrial mucinous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and endometrial mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Endometrial Squamous Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for endometrial squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and endometrial squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Endometrial Transitional Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for endometrial transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and endometrial transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Endometrioid Adenocarcinoma +
PR is an inclusion criterion in 1 clinical trial for endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Epithelioid Sarcoma +
PR is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Extrahepatic Cholangiocarcinoma +
PR is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Fallopian Tube Endometrioid Adenocarcinoma +
PR is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Follicular Lymphoma +
PR is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Gastric Diffuse Adenocarcinoma +
PR is an inclusion criterion in 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and gastric diffuse adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gastrointestinal Neuroendocrine Tumors +
PR is an inclusion criterion in 1 clinical trial for gastrointestinal neuroendocrine tumors, of which 1 is open and 0 are closed. Of the trial that contains PR status and gastrointestinal neuroendocrine tumors as inclusion criteria, 1 is phase 2 (1 open) [4].
Germ Cell Tumor +
PR is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains PR status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].
Hypopharyngeal Carcinoma +
PR is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Hypopharyngeal Squamous Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Invasive Papillary Breast Carcinoma +
PR is an inclusion criterion in 1 clinical trial for invasive papillary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and invasive papillary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Kaposi Sarcoma +
PR is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Kidney Carcinoma +
PR is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and kidney carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Laryngeal Carcinoma +
PR is an inclusion criterion in 1 clinical trial for laryngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and laryngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Laryngeal Squamous Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Leiomyosarcoma +
PR is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and leiomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Liposarcoma +
PR is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Lobular Breast Carcinoma +
PR is an inclusion criterion in 1 clinical trial for lobular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and lobular breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Low Grade Ovarian Serous Adenocarcinoma +
PR is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lung Carcinoma +
PR is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lung Neuroendocrine Neoplasm +
PR is an inclusion criterion in 1 clinical trial for lung neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PR status and lung neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Mixed Mesodermal (Mullerian) Tumor +
PR is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains PR status and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [4].
Malignant Ovarian Clear Cell Tumor +
PR is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains PR status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].
Malignant Ovarian Endometrioid Tumor +
PR is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains PR status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].
Malignant Ovarian Serous Tumor +
PR is an inclusion criterion in 1 clinical trial for malignant ovarian serous tumor, of which 1 is open and 0 are closed. Of the trial that contains PR status and malignant ovarian serous tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Thyroid Gland Neoplasm +
PR is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PR status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Malignant Uterine Corpus Neoplasm +
PR is an inclusion criterion in 1 clinical trial for malignant uterine corpus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PR status and malignant uterine corpus neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Mucinous Breast Carcinoma +
PR is an inclusion criterion in 1 clinical trial for mucinous breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and mucinous breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Myxofibrosarcoma +
PR is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and myxofibrosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
NUT Midline Carcinoma Of The Head And Neck +
PR is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains PR status and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [4].
Neuroendocrine Tumor +
PR is an inclusion criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains PR status and neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Non-Clear Cell Renal Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Oral Cavity Carcinoma +
PR is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Oral Cavity Squamous Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Oropharyngeal Carcinoma +
PR is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Osteosarcoma +
PR is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ovarian Carcinosarcoma +
PR is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and ovarian carcinosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ovarian Granulosa Cell Tumor +
PR is an inclusion criterion in 1 clinical trial for ovarian granulosa cell tumor, of which 1 is open and 0 are closed. Of the trial that contains PR status and ovarian granulosa cell tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Pancreatic Neuroendocrine Carcinoma +
PR is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and pancreatic neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Pancreatic Neuroendocrine Neoplasm +
PR is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PR status and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Pancreatic Neuroendocrine Tumor +
PR is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains PR status and pancreatic neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Papillary Renal Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Penile Carcinoma +
PR is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Peripheral T-Cell Lymphoma, Not Otherwise Specified +
PR is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains PR status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].
Peritoneal Malignant Mesothelioma +
PR is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PR status and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Biphasic Mesothelioma +
PR is an inclusion criterion in 1 clinical trial for pleural biphasic mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PR status and pleural biphasic mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Epithelioid Mesothelioma +
PR is an inclusion criterion in 1 clinical trial for pleural epithelioid mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PR status and pleural epithelioid mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Mesothelioma, Sarcomatoid Type +
PR is an inclusion criterion in 1 clinical trial for pleural mesothelioma, sarcomatoid type, of which 1 is open and 0 are closed. Of the trial that contains PR status and pleural mesothelioma, sarcomatoid type as inclusion criteria, 1 is phase 1 (1 open) [4].
Primary Peritoneal Carcinosarcoma +
PR is an inclusion criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Prostate Undifferentiated Carcinoma +
PR is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Renal Pelvis And Ureter Carcinoma +
PR is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Rhabdoid Tumor +
PR is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains PR status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].
Salivary Gland Carcinoma +
PR is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and salivary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Sarcomatoid Carcinoma +
PR is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Small Intestinal Adenocarcinoma +
PR is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Squamous Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Squamous Cell Carcinoma Of The Penis +
PR is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains PR status and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 1 (1 open) [4].
Synovial Sarcoma +
PR is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
T-Cell And NK-Cell Neoplasm +
PR is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PR status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Tenosynovial Giant Cell Tumor +
PR is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are closed. Of the trial that contains PR status and tenosynovial giant cell tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Tenosynovial Giant Cell Tumor, Diffuse Type +
PR is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, diffuse type, of which 1 is open and 0 are closed. Of the trial that contains PR status and tenosynovial giant cell tumor, diffuse type as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Follicular Carcinoma +
PR is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
PR is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Transformed Non-Hodgkin Lymphoma +
PR is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Transitional Cell Carcinoma +
PR is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Tubular Breast Carcinoma +
PR is an inclusion criterion in 1 clinical trial for tubular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and tubular breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ureter Carcinoma +
PR is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ureter Urothelial Carcinoma +
PR is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Urethral Carcinoma +
PR is an inclusion criterion in 1 clinical trial for urethral carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and urethral carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Uterine Corpus Carcinosarcoma +
PR is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Uterine Sarcoma +
PR is an inclusion criterion in 1 clinical trial for uterine sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and uterine sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Uveal Melanoma +
PR is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Vaginal Carcinoma +
PR is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Well-Differentiated Thyroid Gland Carcinoma +
PR is an inclusion criterion in 1 clinical trial for well-differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR status and well-differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
